Table 3.
Disease | Target | Administration | Delivery System | Ref. |
---|---|---|---|---|
Asthma | GATA3 | Inhalation | Tf-Mel-PEI | [40] |
Asthma | Chil3, Chil4 | Intratracheal Administration |
HMG-OR | [43] |
Asthma | VDBP | Intra-tracheal instillation |
DEXA-PEI | [44] |
Asthma | c-Kit | Intranasal administration |
Modified siRNA | [45] |
Asthma | SOCS3 | Intranasal administration |
Naked siRNA | [46] |
Asthma | Syk | Intranasal administration |
Naked siRNA | [47] |
COPD | RIP2 | Intratracheal administration |
Naked siRNA | [48] |
COPD | RPS3 | Intratracheal administration |
Naked siRNA | [49] |
COPD/ILD | Cytokine Signaling |
Nasal instillation | CaP-PLGA | [41] |
COPD | MAP3K19 | Intratracheal administration |
Naked siRNA | [50] |
Notes: Tf, transferrin; Mel, melittin; PEI, polyethyleneimine; HMG, high mobility group; OR, oligoarginine; DEXA-PEI, dexamethasone-conjugated polyethyleneimine; CaP, calcium phosphate nanoparticles; PLGA, poly(lactic-co-glycolic acid).